Long-term Registry Study on Treatment and Management of Helicobacter pylori Infection in Adults Aged 18 to 80 in Shandong Province

What this Trial Is About

Helicobacter pylori infection is a widespread gastrointestinal disease affecting about 43.1% of people worldwide. Eradicating this infection is important to reduce risks of gastritis, peptic ulcers, and gastric cancer. Because treatment effectiveness can vary due to factors like antibiotic resistance, smoking, body surface area, genetic differences, patient compliance, and regional differences, this research aims to evaluate various treatment regimens in real-world clinical practice over a long term. This study observes patients receiving Helicobacter pylori treatment regimens prescribed by doctors according to current guidelines and tailored to each patients situation. It does not involve any intervention or experimental procedure. The study collects data on different treatment strategies, including the use of 14-day high-dose dual therapy and bismuth-containing quadruple therapy, which are recommended first-line treatments. Participants will be monitored through follow-up tests at least six weeks after completing treatment to measure eradication rates. Adverse events are recorded immediately after treatment completion. The study gathers ongoing real-world evidence to understand the effectiveness, safety, and cost-effectiveness of treatments, helping to inform clinical practice. The total participation covers treatment and follow-up over weeks, with no extra interventions beyond regular care.

Registry for the Management of Helicobacter Pylori Infection in Shandong Province